The GSE1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-mediated gene disruption product targeting the GSE1 locus in a human colorectal adenocarcinoma background. This polyclonal knockout population is generated via non-homologous end joining following Cas9 nuclease activity, yielding a heterogeneous mixture of edited alleles that collectively abrogate functional GSE1 expression. The product serves as a loss-of-function model for investigating the SCF E3 ubiquitin ligase complex and its regulatory roles in protein homeostasis and oncogenic signaling. As a polyclonal preparation, it recapitulates the genetic diversity of pooled knockouts, making it well-suited for population-level studies of ubiquitin-dependent pathways without requiring single-cell cloning.
HT29 is a widely utilized colorectal adenocarcinoma cell line derived from a primary tumor in a 44-year-old female. These epithelial cells exhibit an adherent, undifferentiated morphology and retain key features of intestinal epithelial biology, including expression of mucins, tight junction proteins, and active signaling cascades relevant to colon carcinoma. The cell line is a standard in vitro platform for interrogating colorectal cancer mechanisms, including proliferation kinetics, apoptosis, and chemosensitivity. Its well-characterized mutational landscape??e.g., BRAF V600E and SMAD4 alterations??provides a defined oncogenic context for evaluating the functional consequences of GSE1 ablation in a disease-relevant setting.
GSE1 encodes a coiled-coil domain-containing protein that functions as an integral component of the SCF E3 ubiquitin ligase complex, where it associates with CUL1, SKP1, and RBX1 to mediate substrate recognition. Through this scaffolding role, GSE1 facilitates the ubiquitination of key cell cycle regulators, including Cyclin D1, p21, and p27, targeting them for 26S proteasomal degradation. The protein is regulated by upstream mitogenic signaling molecules and cell cycle regulatory kinases, positioning it at the nexus of pathways such as Wnt, MAPK/ERK, and PI3K/AKT. Disruption of GSE1 impairs assembly or substrate selectivity of the SCF complex, leading to accumulation of downstream targets and consequent dysregulation of cell cycle progression and survival signaling.
In the HT29 colorectal cancer model, GSE1 knockout has profound implications given the critical role of ubiquitin-mediated proteolysis in maintaining oncogenic homeostasis. Loss of GSE1-dependent degradation stabilizes Cyclin D1, p21, and p27, which can alter G1/S transition dynamics, modulate apoptotic thresholds, and influence cellular responses to growth factor cues transduced by MAPK/ERK and PI3K/AKT. This creates a tractable system for studying how ubiquitination defects shape colorectal tumor biology, including perturbations in proliferation, chemoresistance, and feedback loops within oncogenic networks. The polyclonal knockout pool provides a robust platform to systematically examine functional interactions between the SCF complex and pro-tumorigenic pathways.
Researchers can employ this knockout product for a wide array of mechanistic and translational studies. Typical applications include dissecting GSE1-dependent substrate ubiquitination via western blotting for ubiquitinated proteins, co-immunoprecipitation to map SCF complex dynamics, flow cytometry-based cell cycle analysis, and colony formation assays to assess long-term proliferative capacity. The model is also valuable for drug sensitivity screening with proteasome inhibitors such as bortezomib, viability assays (MTT), and transcriptomic profiling by RNA-seq to uncover downstream effectors. These experimental routes enable functional characterization of the ubiquitin-proteasome system in colorectal cancer and may inform identification of synthetic lethal vulnerabilities. For technical inquiries and ordering information, please contact Ascent Research.
